Pioglitazone for patients with type 2 diabetes and nonalcoholic steatohepatitis

Hepatology

Volumn 45, Issue 3, 2007, Pages 827-829

  King, Janet ^a   Kowdley, Kris V ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; INSULIN; PIOGLITAZONE; PLACEBO;

BODY FAT DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FATIGUE; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; INSULIN SENSITIVITY; LEG EDEMA; LIVER BIOPSY; LIVER FIBROSIS; LOW CALORY DIET; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NOTE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMBINANT INBRED STRAIN; TREATMENT RESPONSE;

EID: 33947398877     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21618     Document Type: Note

References (11)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremburg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. HEPATOLOGY 2004;40:1387-1395.
2. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullogh AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and padiological severity. Gastroenterology 1999;116:1413-1419
3. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40(Suppl 1):S17-S29.
4. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791.
5. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
6. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 Weeks of treatment with the PPAR-γ ligand rosiglitazone. HEPATOLOGY 2003;38:1008-1017.
7. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. HEPATOLOGY 2004;39:188-196.
8. Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004;2:1107-1115.
9. Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138
10. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. HEPATOLOGY 2004;39: 770-778
11. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355:2297-2307.